Table 1 (abstract P36). ISR-AEs over the 12-week DBTP, n (%)
| Â | Erenumab, mg | ||
|---|---|---|---|
Placebo (N=1043) | 70 (N=893) | 140 (N=507) | |
Any ISR-AE | 33 (3.2) | 50 (5.6) | 23 (4.5) |
ISR-AEs with >0.5% frequency in any group | |||
 Injection site pain | 18 (1.7) | 33 (3.7) | 8 (1.6) |
 Injection site erythema | 2 (0.2) | 9 (1.0) | 10 (2.0) |
 Injection site pruritus | 3 (0.3) | 4 (0.4) | 4 (0.8) |